Bioporto A/S logo

BIOPOR - Bioporto A/S News Story

DKK5.21 -0.2  -3.0%

Last Trade - 3:59pm

Sector
Industrials
Size
Small Cap
Market Cap £167.6m
Enterprise Value £156.3m
Revenue £2.71m
Position in Universe 759th / 1830

BRIEF-Bioporto Says Expects To Complete Clinical Study And Submit A De Novo Application To FDA For Pediatric Use Of NGAL Test This Summer

Wed 3rd March, 2021 5:47pm
March 3 (Reuters) - Bioporto A/S  BIOPOR.CO :
    * REG-PIPELINE UPDATE FROM BIOPORTO
    * EXPECTS TO COMPLETE CLINICAL STUDY AND SUBMIT A DE NOVO
APPLICATION TO FDA FOR PEDIATRIC USE OF NGAL TEST™ THIS SUMMER
    * BIOPORTO AWAITS US TEST RESULTS FOR RAPID GRAD-BASED
SARS-COV-2
ASSAY
    * IF RESULTS FOR RAPID GRAD-BASED SARS-COV-2 ASSAY IS
POSITIVE,
COMPANY WILL PROCEED TOWARDS EUA AND CE MARK IN Q2 OF 2021

Source text for Eikon:  ID:nGNEbbWgy6 
Further company coverage:  BIOPOR.CO 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.